Gevokizumab

Drug Profile

Gevokizumab

Alternative Names: S-78989; XMA-005.2; XMA-0052; XOMA-052

Latest Information Update: 29 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Servier; University of Zurich; XOMA
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Behcet's syndrome; Pyoderma; Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase II Acne vulgaris; Acute coronary syndromes; Diabetic nephropathies; Giant cell arteritis; Labyrinthitis; Myositis; Osteoarthritis; Schnitzler syndrome; Scleritis
  • Suspended Rheumatoid arthritis
  • No development reported Cancer; Gout; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Pyoderma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Aug 2017 XOMA market-licenses gevokizumab to Novartis worldwide and grants Novartis a license to intellectual property rights for IL-1 beta targeting antibodies for Cardiovascular disorders
  • 09 Jun 2017 Phase II development for Acne vulgaris and Osteoarthritis is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top